Literature DB >> 12658802

Apoptosis of leukemia cells induced by CD34+ cells transferred exogenous Fas ligand.

Juan Xiao1, Ping Zou, Zhongwen Liu, Zhongbo Hu, Lingbo Liu.   

Abstract

To assess the value of CD34+ cells transferred exogenous Fas ligand (FasL) in inducing apoptosis of human leukemic cells, the CD34+ cells transfected with FasL or without, pretreated with mitomycin C, was mixed with leukemic cell line U937 cells in presence or absence of daunorubicin (DNR) or cytosine arabinoside (Ara-C). After 18 h, apoptosis of cells was detected by FCM and TUNEL. Induced for 18 h by CD34+ cells transfected with FasL or without, the ratio of apoptosis of U937 cells was (5.0 +/- 1.3)%, (10.8 +/- 0.6)% (P < 0.01), respectively. Induced by FasL+ CD34+ + DNR, FasL+ CD34+ + Ara-C, the ratio was (13.4 +/- 1.0)% (P < 0.05), (17.9 +/- 1.3)% (P < 0.01), respectively. The result demonstrated that CD34+ cells transfected with exogenous FasL could induce apoptosis of human leukemic cells and showed a cytotoxic synergistic effect when used in combination with chemotherapeutic drugs, suggesting that it was possible to develop a new method in treatment of leukemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12658802     DOI: 10.1007/BF02828178

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  3 in total

1.  Anti-Fas IgM monoclonal antibody enhances apoptosis induced by low-dose cytosine arabinoside.

Authors:  S Nakamura; M Takeshima; Y Nakamura; S Ohtake; T Matsuda
Journal:  Anticancer Res       Date:  1999 Jan-Feb       Impact factor: 2.480

2.  Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines.

Authors:  W Dirks; S Schöne; C Uphoff; H Quentmeier; S Pradella; H G Drexler
Journal:  Br J Haematol       Date:  1997-03       Impact factor: 6.998

3.  Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.

Authors:  A Younes; V Snell; U Consoli; K Clodi; S Zhao; J L Palmer; E K Thomas; R J Armitage; M Andreeff
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.